ArticleDiscover oncology2025
Targeting the LINC00265/miR-485-5p axis for diagnosis and therapeutic intervention in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of breast cancer ranks first among female tumors. Early diagnosis and treatment of breast cancer can effectively alleviate the suffering of patients, and attention to breast cancer diagnostic markers may provide a new theoretical basis for biological therapy. PURPOSE: The objective of this study was to investigate the diagnostic value of LINC00265 in breast cancer and to elucidate its pathological mechanisms.
methodsThere were 88 breast cancer patients as the experimental subjects and 72 healthy individuals as the control group. LINC00265 and miR-485-5p levels in serum and cell supernatants were determined by RT-qPCR analysis. Cell function was evaluated via CCK-8 and Transwell assays. The sponge function of LINC00265 on miR-485-5p was confirmed by conducting a dual-luciferase activity assay.
resultsLINC00265 was highly expressed, and miR-485-5p was downregulated in breast cancer. LINC00265 has diagnostic value in breast cancer and is closely related to lymphatic metastasis and TNM stage in patients. Silencing LINC00265 suppressed cell function, while knockdown of miR-485-5p restored this regulation.
conclusionSignificantly upregulated LINC00265 is a biomarker for the diagnosis of breast cancer, and LINC00265 binds to miR-485-5p to mediate tumor progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.